The company will continue to offer both the Aperio and the existing Leica portfolio of Digital Pathology solutions, so that customers will enjoy more freedom to choose a solution that meets their individual needs. Together, the two companies plan to grow and expand digital pathology into the global Life Science and Healthcare markets providing industry leading solutions in each step of the anatomical pathology workflow, from sample preparation and staining, to imaging and reporting. Bioptigen manufactures and sells SDOCT systems from the company’s Morrisville, North Carolina operations center.Leica Biosystems announced yesterday that an affiliate has entered into a definitive agreement to acquire Aperio, a leading provider of ePathology solutions.Īperio will be integrated into Leica Biosystems, a leader in anatomical pathology solutions and which is itself a part of the Danaher Group of companies. Deployed in top ophthalmic research and clinical institutions worldwide, Bioptigen SDOCT systems are supported by over 40 awarded patents. About BioptigenĪs a pioneer in the development and manufacture of leading edge Spectral Domain Optical Coherence Tomography (SDOCT) equipment and software, Bioptigen is helping researchers explore the wonders of ocular development and the mysteries of ocular disease. Its headquarters are located in Wetzlar, Germany. The company is represented in over 100 countries, has sales and service organizations in 20 countries, and an international network of distribution partners. Leica Microsystems has seven major plants and product development sites around the world. It is one of the market leaders in compound and stereo microscopy, digital microscopy, confocal laser scanning microscopy with related imaging systems, electron microscopy sample preparation, and surgical microscopes. Ever since the company started as a family business in the nineteenth century, its instruments have been widely recognized for their optical precision and innovative technology. Leica Microsystems develops and manufactures microscopes and scientific instruments for the analysis of microstructures and nanostructures. Together, we believe we can jointly leverage our ophthalmic imaging technologies, address broader research and clinical markets, and more efficiently complete the next steps in integrating OCT imaging capabilities into the operating room.” About Leica Microsystems Bioptigen brings great products and expertise, and will be an important contributor to our growth in the ophthalmology market.”Įric Buckland, CEO of Bioptigen, says: “We are delighted to join Leica Microsystems. Heinrich Dreyer, Vice President of Leica Microsystems’ Medical Division, says: “Adding Bioptigen’s OCT capabilities to our surgical microscopes directly addresses our customers’ requirement for better decision making tools. This non-invasive technique is used to detect and monitor morphological changes of ocular tissue, in particular retinal layer thickness, which can give insight into pathological conditions such as glaucoma, age-related macular degeneration (AMD) or diabetic retinopathy. OCT utilizes interferometry to create cross-sectional views of different types of tissue. Bioptigen currently markets the FDA-cleared and CE-marked Envisu C2300 OCT for handheld, pediatric, and perioperative applications, and sells advanced ophthalmic OCT imaging systems for preclinical research globally. Using low-power, near-infrared light, Bioptigen OCTs generate high-resolution, volumetric images of the eye. The integration of OCT imaging into Leica Microsystems’ surgical microscopes will assist ophthalmologists during eye surgery.īioptigen develops and manufactures innovative OCT systems and software and is globally successful with products for clinical as well as translational research applications. ![]() Bioptigen is a technology leader in the field of optical coherence tomography (OCT). to strengthen its position in the ophthalmology market. Leica Microsystems, a global leader in microscopy and imaging systems, has signed a definitive agreement to acquire Bioptigen, Inc. Wetzlar, Germany / Morrisville, North Carolina, USA. ![]() ![]() Integration of Optical Coherence Tomography (OCT) Opens up New Avenues for Ophthalmology and Life Science Research
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |